Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
ASCO Breakthrough 2026
ASCO 2026
ESTRO 2026
AACR 2026
EBCC15
Calendar
View All
Topics
AI in Oncology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Geriatrics for the Oncologist,Geriatrics for the Oncologist
Advertisement
Advertisement
Jun
30
Today In Oncology
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers
Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs
Long-Term Outcomes With SABR in Primary Kidney Cancer
View More
Advertisement
